European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Nasdaq1mon
Biogen's Q3 2024 Earnings: What to Expect
Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $26.6 bi ...
The Business Journals25d
Biogen raises 2024 outlook on strong Alzheimer's drug sales
the Alzheimer's disease drug it developed in partnership with Eisai Inc. The Cambridge biotech said it's increasing its 2024 financial guidance in its third-quarter earnings on Wednesday. Biogen ...
Hosted on MSN11d
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Based in Cambridge, MA, Biogen Inc. is one of the world’s leading biotechnology companies, which focuses on ...
The Boston Globe25d
Biogen raises forecast as Alzheimer’s drug Leqembi shows signs of growth
the Cambridge-based company said Wednesday in a statement. While that’s a 6 percent decline from a year earlier, it beat analysts’ estimates. The results could help Biogen start to restore ...
Seeking Alpha23d
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
Biogen Inc. (NASDAQ:BIIB) the central nervous system disease drug developer based in Cambridge Massachusetts, reported its Q3 earnings yesterday, Wednesday, October 30. First, let's look at some ...
Petri Dish: Kronos Bio seeks merger; Former Biogen R&D head joins investment firm
Happenings in Boston’s life sciences ecosystem this past week include the departure of a general partner from Apple Tree Partners for another firm, Kronos Bio seeks "strategic alternatives" and new ...
Morningstar25d
Biogen's stock hit by soft sales of Alzheimer's treatment
Biogen Inc.'s stock shed early gains to trade ... and that overall product revenue was about $80 million below consensus. The Cambridge, Mass.-based company (BIIB) had net income of $388.5 million ...
FierceBiotech25d
Biogen buys in to molecular glues with Neomorph deal worth up to $1.45B
Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZâ„¢
OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen’s partnershipEC ...